Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Strategies Needed for Resistance to Targeted Agents in HER2+ Breast Cancer

Brandon Scalea
Published: Tuesday, Jan 15, 2019

Dr Mothaffar F. Rimawi

Mothaffar F. Rimawi, MD
HER2-directed agents and chemotherapy have dramatically improved the outlook for patients with HER2-positive breast cancer, but researchers are still scratching the surface in understanding the biology of the disease and resistance mechanisms, said Mothaffar F. Rimawi, MD.

, Rimawi, an associate professor and director of Clinical Research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discussed the current options in HER2-positive breast cancer and shed light on where future research is headed.

OncLive: Could you describe the metastatic HER2-positive breast cancer paradigm?

Rimawi: The landscape of metastatic HER2-positive breast cancer is evolving very rapidly. It is evolving because of several factors. In the early-stage setting, [there are] increased reports from clinical trials showing benefits from anti-HER2 agents, such as pertuzumab and neratinib (Nerlynx) and, most recently, results from the KATHERINE study on T-DM1. [These agents] are improving patient outcomes in the early-stage setting, but they are also using them in the metastatic setting and moving them earlier. That is likely to affect how those agents are used, if they are used again in the metastatic setting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication